Dr. Namandjé N. Bumpus Principal Deputy Commissioner - FDA | Official Website
Dr. Namandjé N. Bumpus Principal Deputy Commissioner - FDA | Official Website
This is a 700% increase over the number of companies cited in the previous year.
Of the 22 citations issued, the most common citations were 'A process whose results cannot be fully verified by subsequent inspection and test has not been adequately validated according to established procedures' and 'Procedures for corrective and preventive action have not been adequately established'.
Most of the companies cited were involved in either Devices or Drugs sectors.
All of the companies cited should take voluntary actions to correct their managing operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
Company Name | Area of Business | Inspection Date | Issue Cited |
---|---|---|---|
Addivation Medical | Devices | 01/12/2023 | Design changes - Lack of or Inadequate Procedures |
Addivation Medical | Devices | 01/12/2023 | Purchasing controls, Lack of or inadequate procedures |
Addivation Medical | Devices | 01/12/2023 | Lack of or inadequate process validation |
Addivation Medical | Devices | 01/12/2023 | Lack/Inad procedure-Monitoring/Control of Validated Proces |
Addivation Medical | Devices | 01/12/2023 | Lack of or inadequate procedures for labeling |
Addivation Medical | Devices | 01/12/2023 | DMR - not or inadequately maintained |
Airgas USA, LLC | Drugs | 06/21/2023 | Distinctive ID or code not recorded in batch record |
Airgas USA, LLC | Drugs | 06/21/2023 | Complete Test Data |
Airgas USA, LLC | Drugs | 06/21/2023 | Procedures to be written and followed |
Dimensional Merchandising, Inc. | Drugs | 04/18/2023 | Written procedures not established/followed |
Dimensional Merchandising, Inc. | Drugs | 04/18/2023 | Computer control of master formula records |
Dimensional Merchandising, Inc. | Drugs | 04/18/2023 | Identity Testing of Each Component |
Dimensional Merchandising, Inc. | Drugs | 04/18/2023 | Annual visual exams of drug products |
Life Recovery Systems HD, LLC | Devices | 09/11/2023 | Nonconforming product, Lack of or inadequate procedures |
Life Recovery Systems HD, LLC | Devices | 09/11/2023 | Lack of or inadequate procedures |
Novartis Pharmaceuticals Corporation | Drugs | 08/21/2023 | General responsibilities of sponsors |
Shriji Marketing, Inc. | Food and Cosmetics | 01/30/2023 | Develop FSVP |
Sterigenics U. S., LLC | Devices | 08/15/2023 | Calibration, Inspection, etc. Procedures Lack of or Inadequ |
Sterigenics U. S., LLC | Devices | 08/15/2023 | Remedial action |
Sterigenics U. S., LLC | Devices | 08/15/2023 | Lack of or inadequate process validation |
Sterigenics U. S., LLC | Devices | 08/15/2023 | Lack of or inadequate procedures |
Tnuva USA, Inc. | Food and Cosmetics | 04/20/2023 | Hazard analysis biological, chemical, physical |